hepatocellular carcinoma
Conditions
Interventions
AFP derived peptides
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically diagnosed as hepatocellular carcinoma 2) Conducted transarterial chemoembolization 3) Complete response to transarterial chemoembolization 4) Recovery from adverse events for transarterial chemoembolization 5) HLA A24 6) Child Pugh classification A or B 7) 20 years or older 8) ECOG Performance status 0, 1 or 2 9) Reserved major organ function Neutrophil 1,000/mm3 or more; Hemoglobin 8.0 g/dl or more; Platelet 40,000 /mm3 or more; Total bilirubin 3.0 mg/dl or less 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Refractory ascites or pleural effusion 2) History of hepatic encephalopathy within 3 months 3) Risky varices 4) Active double cancer 5) Transfusion of RCC, PC, FFP, or G-CSF within 2 weeks 6) Administration of steroid or immuno suppressive agents 7) Severe complication 8) Systemic infection (excluded viral hepatitis) 9) Pregnant or lactating women, or women of childbearing potential 10) Mental disorder 11) Allergy for AFP derived peptides or adjuvant 12) Allergy for contrast agent of CT or/and MRI 13) Inappropriate candidate for this study judged by doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe adverse events | — |
Countries
Japan
Contacts
Public ContactTakeshi Terashima
Kanazawa University Hospital Department of Gastroenterology
Outcome results
None listed